| UPDATED: 19:18, Tue, Feb 2, 2021
Link copied Sign up for FREE health tips to live a long and happy life
SUBSCRIBE Invalid email
When you subscribe we will use the information you provide to send you these newsletters.
Sometimes they ll include recommendations for other related newsletters or services we offer.
Our Privacy Notice explains more about how we use your data, and your rights.
You can unsubscribe at any time.
The UK government is facing growing pressure to crack down on border controls to stop more cases of the South Africa strain from entering the UK. The variant, known as B.1.351, has already been discovered in a small number of people in the UK. While there is no evidence to suggest the South Africa strain is more deadly than other mutations, fears that it could elude the vaccines are raising the temperature.
Ayrshire nurse is struck off after being branded dishonest
dailyrecord.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyrecord.co.uk Daily Mail and Mail on Sunday newspapers.
Ease of use
Most respondents who answered the question on ease of use agreed or strongly agreed that Patientrack was easy to use (Fig 2). However, 47% (27 out of 57) reported that using the system took longer than the paper version; this finding has been explored further in a subsequent study, which is yet to be published. It appears staff valued Patientrack, as 66% of respondents (36 out of 54) felt it should be rolled out to the rest of the hospital.
Clinical areas that frequently use bank or agency staff reported finding it challenging, at times, to ensure appropriately trained staff were available to record patients’ vital signs on the electronic system. Technical challenges (for example, passwords expiring and problems accessing log-in details) were also reported; these prevented some staff members from electronically recording vital signs.
Chong Kun Dang headquarters located in Chungjeong-ro, Seodaemun-gu, Seoul. [Photo Chong Kun Dang]
SEOUL: Chong Kun Dang, a South Korean pharmaceutical company, has announced that the effectiveness of COVID-19 treatment “Nafabeltan” at clinical trials has been proven.
Nafabeltan is effective in treating COVID-19 patients with more severe conditions.
“Nafabeltan has excellent treatment effects for high-risk patients,” an official from Chong Kun Dang said on January 14.
COVID-19 patients are classified as ‘’Mild’ patients who do not require hospitalization, ‘Moderate’ patients who need oxygen mask treatment and ‘Severe’ patients who need intensive care (ICU) treatment or equipped with ventilators.
When National Early Warning Score (NEWS) predicts the fatality of pneumonia patients due to COVID-19, among severe patients, is 7 points or more, the probability of death increases 18 times, and is classified as a ‘high-risk group’.
ADVERTISING FEATURE
18 December, 2020
Interneuron has developed an electronic solution for early warning scores for use by the nursing team at Royal National Orthopaedic Hospital NHS Trust. Claire Read reports
When the Royal National Orthopaedic Hospital NHS Trust decided to introduce a new electronic solution for early warning scores, the nursing team was made an interesting offer. Members were asked to come along to an early testing session for the new software and given a very clear, very specific, very express instruction: to try their absolute hardest to break this early version of the program.
“We had a very rough working prototype and we took it, and them, into a room and said: ‘Look, this is what we’ve got; please break it,’” remembers Matt Phillips, lead clinical practitioner for the acute intervention and clinical site team and simulation and resuscitation services.
vimarsana © 2020. All Rights Reserved.